Article
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?
23 Dec 2024
Abstract excerpt
For the past few years, researchers and oncologists have been pushing to find biomarkers that would help predict which treatment option would best work on a patient. Tumor Mutational Burden (TMB) is one of the latest biomarkers that is being studied and considered as a promising agnostic immunotherapy biomarker. However, it still shows controversial results in studies due to the difficulty in finding solid...
Topics
Join the communities discussing this publication.